Lexeo Therapeutics Announces Positive Interim Phase I/II Data and Regulatory Update for LX2020 in PKP2 Arrhythmogenic Cardiomyopathy and Reports Third Quarter 2026 Financial Results
GlobeNewswire · 财报与经营业绩 · November 16, 2026 at 7:00 AM ET
Read the full report at the original publisher.